Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Exposure analysis using X-ray fluorescence device and a cobalt spot test in four patients with cobalt allergy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Interaction between filaggrin mutations and neonatal cat exposure in atopic dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Chronologic order of appearance of immune-mediated inflammatory diseases relative to diagnosis of psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Several novel biologics are available or in development for moderate-to-severe plaque psoriasis. These drugs may differ in time until Psoriasis Area and Severity Index (PASI) response is obtained. In this systematic review, we examined the time to onset of action for interleukin (IL)-17 and IL-23 agents in the treatment of psoriasis. The primary objective was the weighted mean time needed for 25% and 50% of patients with psoriasis to achieve PASI90. The medical databases PubMed, Web of Science and EMBASE were searched using the following terms: psoriasis AND (ixekizumab OR secukinumab OR brodalumab OR risankizumab OR guselkumab OR tildrakizumab). A total of 27 studies were included for data extraction and qualitative synthesis, and 26 of these were quantitatively analysed. The shortest time to 25% and 50% of patients to achieved PASI90 were seen with brodalumab 210 mg every 2 weeks (Q2W; 3.5 weeks and 6.2 weeks, respectively) followed by ixekizumab 80 mg Q2W (4.1 and 7.4 weeks, respectively) and ixekizumab 80 mg Q4W (4.6 and 8.1 weeks, respectively) dosages. In conclusion, clinical trials yielded shorter time to onset of action in studies assessing approved dosing ranges of IL-17 inhibitors compared with studies assessing IL-23 inhibitors.

Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
Volume34
Issue number1
Pages (from-to)39-46
Number of pages8
ISSN0926-9959
DOIs
Publication statusPublished - Jan 2020

ID: 59077149